Olanzapine - A pharmacoeconomic review of its use in schizophrenia

被引:50
作者
Foster, RH [1 ]
Goa, KL [1 ]
机构
[1] Adis Int Ltd, Auckland 10, New Zealand
关键词
olanzapine; schizophrenia; pharmacoeconomics; cost effectiveness; quality of life; therapeutic use;
D O I
10.2165/00019053-199915060-00008
中图分类号
F [经济];
学科分类号
02 ;
摘要
Sources: Medical literature published in any language since 1966 on olanzapine, identified using AdisBase (a proprietary database of Adis International, Auckland, New Zealand) and Medline. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: AdisBase search terms were 'olanzapine' or 'schizophrenia' and ('health-economics' or 'pharmacoepidemiology' or 'prescribing' or 'hospitalisation' or 'formularies' or 'drug-utilisation' or 'meta-analysis' or 'therapeutic-substitution' or 'epidemiology'), or 'olanzapine' and 'schizophrenia', Medline search terms were 'olanzapine' or 'schizophrenia' and ('economics' or 'health-policy' or 'quality-of-life' or 'models-statistical' or 'health-planning' or 'epidemiology' or 'guideline in pt' or 'practice-guidelines in pt'. Searches were last updated 26 April 1999, Selection: Economic and quality-of-life analyses in patients with schizophrenia or related psychotic disorders who received olanzapine. inclusion of studies was based mainly on the methods section of the trials. Relevant background data on epidemiology, cost of illness and therapeutic use of olanzapine are also included.
引用
收藏
页码:611 / 640
页数:30
相关论文
共 121 条
[1]   Cost analysis of the treatment of schizophrenia in the UK - A comparison of olanzapine and haloperidol [J].
Almond, S ;
O'Donnell, O .
PHARMACOECONOMICS, 1998, 13 (05) :575-588
[2]   ASSESSMENT ISSUES AND THE COST OF SCHIZOPHRENIA [J].
ANDREASEN, NC .
SCHIZOPHRENIA BULLETIN, 1991, 17 (03) :475-481
[3]  
[Anonymous], 1993, AM J PSYCHIAT, V150, P1447
[4]  
[Anonymous], 1998, J Clin Psychiatry, V59 Suppl 12, P41
[5]   Measuring quality of life in patients with schizophrenia [J].
Awad, AG ;
Voruganti, LNP ;
Heslegrave, RJ .
PHARMACOECONOMICS, 1997, 11 (01) :32-47
[6]  
Baldacchino AM., 1998, PHARM J, V260, P207
[7]  
Beasley CM, 1997, J CLIN PSYCHIAT, V58, P13
[8]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[9]   Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial [J].
Beasley, CM ;
Hamilton, SH ;
Crawford, AM ;
Dellva, MA ;
Tollefson, GD ;
Tran, PV ;
Blin, O ;
Beuzen, JN .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) :125-137
[10]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123